Immunotherapy in Ovarian Cancer:(IGWHC)-Lupine Publishers
Ovarian cancer ranks fifth with a 5-year survival of 40%
for patients with advanced disease and remains the most lethal
gynecologic malignancy among women [1]. Most patients with
advanced disease undergo aggressive frontline treatments with
surgery and adjuvant chemotherapy; however, 80% of patients
ultimately recur within few months and develop chemoresistant
disease [2]. Advances in traditional treatment regimens and
addition bevacizumab as a targeted therapy have shown promising
results with improved progression-free survival but overall survival
rates still remains the unaltered.
For more Lupine Publishers Open Access Journals Please visit our website: http://www.lupinepublishers.com/
For more Healthcare Open Access Journal articles Please Click Here: http://www.lupinepublishers.com/gynecology-women-health-journal/
For more Healthcare Open Access Journal articles Please Click Here: http://www.lupinepublishers.com/gynecology-women-health-journal/
Comments
Post a Comment